Tebentafusp: The First FDA-approved Monoclonal Antibody for Cancer Treatment in 2022

Pouya  Safarzadeh Kozani; Pooria Safarzadeh Kozani; Abdolkarim Sheikhi

doi:10.5812/tms.123546

Tebentafusp: The First FDA-approved Monoclonal Antibody for Cancer Treatment in 2022

authors:

Pouya Safarzadeh Kozani ^{#
1} , Pooria Safarzadeh Kozani ^{#
2} , Abdolkarim Sheikhi ^{3
, 4
, *}

1 Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran

2 Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

3 Student Research Committee, Medical Biotechnology Research Center, School of Nursing, Midwifery, and Paramedicine, Guilan University of Medical Sciences, Rasht, Iran

4 Department of Immunology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran

# These authors are contributed equally as the first author.

Trends in Medical Sciences: Vol.1, issue 4; e123546

published online: March 13, 2022

article type: Letter

received: February 22, 2022

accepted: February 23, 2022

DOI: https://doi.org/10.5812/tms.123546

how to cite: Safarzadeh Kozani P , Safarzadeh Kozani P, Sheikhi A. Tebentafusp: The First FDA-approved Monoclonal Antibody for Cancer Treatment in 2022. J Adv Immunopharmacol. 2021;1(4):e123546. https://doi.org/10.5812/tms.123546.

Keywords

Tumor Immunotherapy TCR-scFv Fusion Protein gp100 Tebentafusp

Footnotes

Authors' Contribution: PS, PS, and AS were contributed to writing and revising the manuscript.
Conflict of Interests: The authors declare no conflict of interest.
Ethical Approval: IR.DUMS.REC.1400.006 (Link: ethics.research.ac.ir/ProposalCertificateEn.php?id=192621)
Funding/Support: The Dezful University of Medical Sciences supported this letter.

References

1.
Safarzadeh Kozani P, Naseri A, Safarzadeh Kozani P, Khatami S, Sheikhi A. Monoclonal Antibodies (mAbs) Approved for Cancer Treatment in the 2020s. Trends Med Sci. 2021;1(2). https://doi.org/10.5812/tms.116686.
2.
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021;385(13):1196-206. [PubMed ID: 34551229]. https://doi.org/10.1056/NEJMoa2103485.
3.
Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24. [PubMed ID: 32273508]. https://doi.org/10.1038/s41572-020-0158-0.
4.
van der Kooij MK, Speetjens FM, van der Burg SH, Kapiteijn E. Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. Cancers (Basel). 2019;11(6). [PubMed ID: 31248118]. [PubMed Central ID: PMC6627906]. https://doi.org/10.3390/cancers11060845.
5.
Rantala ES, Hernberg M, Kivela TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561-8. [PubMed ID: 30664106]. [PubMed Central ID: PMC6887637]. https://doi.org/10.1097/CMR.0000000000000575.
6.
Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370-80. [PubMed ID: 31150059]. https://doi.org/10.1093/annonc/mdz176.
7.
Buder K, Gesierich A, Gelbrich G, Goebeler M. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med. 2013;2(5):674-86. [PubMed ID: 24403233]. [PubMed Central ID: PMC3892799]. https://doi.org/10.1002/cam4.133.
8.
FDA. FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma. 2022, [cited 14 February 2022]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma.

comments